The ROE as of November 2024 (TTM) for Finch Therapeutics Group, Inc. (FNCH) is -69.14%

According to Finch Therapeutics Group, Inc.’s latest financial reports and current stock price. The company's current ROE is -69.14%. This represents a change of 259.18% compared to the average of -19.25% of the last 4 quarters.

Finch Therapeutics Group, Inc. (FNCH) Historical ROE (quarterly & annually)

How has FNCH ROE performed in the past?

The mean historical ROE of Finch Therapeutics Group, Inc. over the last ten years is -79.55%. The current -69.14% ROE has changed -13.09% with respect to the historical average. Over the past ten years (40 quarters), FNCH's ROE was at its highest in in the December 2020 quarter at 13.68%. The ROE was at its lowest in in the March 2023 quarter at -194.04%.

Finch Therapeutics Group, Inc. (FNCH) ROE by Quarter and Year

Discovering the peaks and valleys of Finch Therapeutics Group, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Finch Therapeutics Group, Inc. (FNCH) Average ROE

How has FNCH ROE performed in the past?

The current ROE of Finch Therapeutics Group, Inc. (FNCH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Finch Therapeutics Group, Inc. (FNCH) ROE vs. Peers

How is FNCH’s ROE compared to its peers?

Finch Therapeutics Group, Inc.’s ROE is greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Decibel Therapeutics, Inc. (-84.03%), greater than Celcuity Inc. (-60.83%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Ikena Oncology, Inc. (-42.81%), greater than Design Therapeutics, Inc. (-18.48%), greater than Xilio Therapeutics, Inc. (-176.51%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Virax Biolabs Group Limited (-115.10%), greater than Blue Water Vaccines, Inc. (-111.44%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Hillstream BioPharma, Inc. (-47249.59%), less than Kiora Pharmaceuticals, Inc. (15.57%), greater than Nutriband Inc. (-76.31%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Longeveron Inc. (-246.98%), greater than RenovoRx, Inc. (-403.38%),

Build a custom stock screener for Finch Therapeutics Group, Inc. (FNCH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Finch Therapeutics Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Finch Therapeutics Group, Inc. (FNCH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Finch Therapeutics Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.